[{"orgOrder":0,"company":"Kardigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ataciguat","moa":"Soluble guanylate cyclase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kardigan \/ Undisclosed"},{"orgOrder":0,"company":"Kardigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Tonlamarsen","moa":"STAT3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kardigan \/ Undisclosed"},{"orgOrder":0,"company":"Kardigan","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Kardigan","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Perceptive Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Kardigan \/ Perceptive Advisors"},{"orgOrder":0,"company":"Kardigan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Kardigan","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kardigan \/ Undisclosed"},{"orgOrder":0,"company":"Kardigan","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"Danicamtiv","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Kardigan","amount2":0.25,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Kardigan \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"9","companyTruncated":"Kardigan \/ Fidelity Management & Research Company"}]